Fusion Pharmaceuticals Inc.
5 clinical trials · Sponsor
◉ Watch Fusion Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06909825) | Fusion Pharmaceuticals Inc. | 2025-02-26 |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06402331) | Fusion Pharmaceuticals Inc. | 2024-03-05 |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours (NCT05363605) | Fusion Pharmaceuticals Inc. | 2022-04-20 |
| Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (NCT05219500) | Fusion Pharmaceuticals Inc. | 2021-12-16 |
| A Phase 1 Study of [225Ac]-FPI-1434 Injection (NCT03746431) | Fusion Pharmaceuticals Inc. | 2019-01-17 |
Track Fusion Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.